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Aim: The aim of this study was to summarize the characteristics, efficacy, and safety of vesicular 
monoamine transporter-2 (VMAT-2) inhibitors for treating tardive dyskinesia (TD).
Materials and methods: We conducted a literature search in PubMed, Cochrane Database, and 
ClinicalTrials.gov, screening for systematic reviews, meta-analyses or double-blind, randomized, 
placebo-controlled trials (DBRPCTs) reporting efficacy or safety data of VMAT-2 inhibitors 
(tetrabenazine, deutetrabenazine, and valbenazine) in patients with TD. A random effects 
meta-analysis of efficacy and safety data from DBRPCTs was performed.
Results: Two acute, 12-week DBRPCTs with deutetrabenazine 12–48 mg/day (n=413) and 
4 acute, 4–6-week double-blind trials with valbenazine 12.5–100 mg/day (n=488) were meta-
analyzable, without meta-analyzable, high-quality data for tetrabenazine. Regarding reduction 
in total Abnormal Involuntary Movement Scale (AIMS) scores (primary outcome), both deutet-
rabenazine (k=2, n=413, standardized mean difference [SMD] =-0.40, 95% confidence interval 
[CI] =-0.19, -0.62, p,0.001; weighted mean difference (WMD) =-1.44, 95% CI =-0.67, -2.19, 
p,0.001) and valbenazine (k=4, n=421, SMD =-0.58, 95% CI =-0.26, -0.91, p,0.001; 
WMD =-2.07, 95% CI =-1.08, -3.05, p,0.001) significantly outperformed placebo. Results 
were confirmed regarding responder rates ($50% AIMS total score reduction; deutetrabenazine: 
risk ratio [RR] =2.13, 95% CI =1.10, 4.12, p=0.024, number-needed-to-treat [NNT] =7, 95% 
CI =3, 333, p=0.046; valbenazine: RR =3.05, 95% CI =1.81, 5.11, p,0.001, NNT =4, 95% CI =3, 
6, p,0.001). Less consistent results emerged from patient-rated global impression-based response 
(p=0.15) and clinical global impression for deutetrabenazine (p=0.088), and for clinical global 
impression change for valbenazine (p=0.67). In an open-label extension (OLE) study of deutet-
rabenazine (#54 weeks) and a dose-blinded valbenazine study (#48 weeks), responder rates 
increased over time. With valbenazine, discontinuation effects were studied, showing TD symp-
tom recurrence towards baseline severity levels within 4 weeks after valbenazine withdrawal. No 
increased cumulative or specific adverse (AEs) events versus placebo (acute trials) in extension 
versus acute trial data were observed.
Conclusion: The 2 VMAT-2 inhibitors, valbenazine and deutetrabenazine, are effective in 
treating TD, both acutely and long-term, without concerns about increased risk of depression 
or suicide in the TD population. No head-to-head comparison among VMAT-2 inhibitors and 
no high-quality, meta-analyzable data are available for tetrabenazine in patients with TD.
Keywords: tetrabenazine, deutetrabenazine, valbenazine, tardive dyskinesia, VMAT-2
Introduction
Tardive dyskinesia (TD) is a severe1 and potentially irreversible adverse effect of first- 
and second-generation antipsychotics (FGAs and SGAs), with a cumulative annual 
incidence of 5.4%2 to 7.7%3 with FGAs compared to 0.8%2 to 3.0%3 with SGAs in 
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adults, and approximately a 3- to 5-fold higher incidence 
in the elderly, with both FGAs (25%–30%)4,5 and SGAs 
(5%–7%).6 A recent meta-analysis found across 41 studies 
and 11,493 patients (77% diagnosed with schizophrenia) 
pooled TD prevalence of 25.3% in patients treated with antip-
sychotics, with a lower frequency with current SGA treat-
ment (20.7%) than FGA treatment (30.0%), and the lowest 
prevalence in SGA-treated patients without a documented 
lifetime history of FGA treatment (7.2%).7 Proposed risk 
factors for TD include both unmodifiable patient-related and 
illness-related risk factors (higher age, female sex, Caucasian 
race, African descent, longer illness duration, intellectual 
disability and brain damage, negative symptoms in schizo-
phrenia, mood disorder diagnosis, cognitive symptoms in 
mood disorders, and gene polymorphisms involving antip-
sychotic metabolism and dopamine functioning) as well as 
modifiable comorbidity-related and treatment-related factors 
(diabetes, smoking, alcohol and substance abuse, FGA vs 
SGA treatment, higher cumulative or current antipsychotic 
dose or higher antipsychotic plasma levels, early neuromo-
tor syndromes [parkinsonian side effects, acute dystonia], 
anticholinergic co-treatment, akathisia, and subtle/emergent 
dyskinesia).2,3,7–10 
TD can be measured with Abnormal Involuntary Move-
ment Scale (AIMS),11 a 12-item scale with items 1–7 assess-
ing involuntary movements across body regions, with a 
score ranging from 0 (no dyskinesia) to 4 (severe, maximal 
amplitude, and persistence during observation of abnormal 
movements), or with other less frequently used instruments/
scales, such as the Extrapyramidal Symptom Rating 
Scale.12
Although still not conclusively established, 3 main (non-
mutually exclusive) pathogenetic hypotheses of TD have 
been proposed. These include oxidative stress,13 glutamate-
mediated toxicity within striatopallidal or nigrostriatal GABA 
signaling pathways with decreased inhibitory activity in 
nigrostriatal circuits, and dopamine receptor hypersensitivity 
following receptor upregulation due to antidopaminergic 
treatment.14 The latter theory is supported by the worsening 
or un-masking of TD after abrupt cessation of dopamine D2 
blocking agents.15
TD should ideally be prevented. Strategies include 
antipsychotic prescription only when indicated clinically, 
avoiding parkinsonian side effects, using conservative main-
tenance doses, and preferring SGAs over FGAs as first-line 
treatment.3,8,16 However, SGAs are not a homogeneous class 
with regard to parkinsonian adverse effect rates.17 Neverthe-
less, the differential TD risk among individual SGAs, except 
for a likely lowest risk with clozapine, has not been clear. 
In this regard, a recent meta-analysis of annualized incidence 
rate ratios comparing FGAs with SGAs and SGAs with each 
other in RCTs lasting $3 months (median: 1.0 [interquartile 
range =0.44–2.0] years) not only confirmed significantly 
lower TD annualized incidence rates with SGAs as a class 
vs FGAs (NNT =20) but also suggested that olanzapine and 
aripiprazole may have a small, yet statistically significant 
advantage over other non-clozapine SGAs (NNT =100 for 
olanzapine vs non-clozapine SGAs).18 Moreover, in 3 trials 
that compared clozapine to olanzapine or predominant olan-
zapine treatment, olanzapine did not differ from clozapine 
with regard to annualized TD risk. Finally, despite a relatively 
greater risk of parkinsonian side effect and anticholinergic 
co-treatment than many other SGAs,17 risperidone and pali-
peridone had a similar TD risk when compared head-to-head 
with other non-clozapine/non-olanzapine SGAs.18
When TD is present, a number of treatment approaches 
have been tested, including antipsychotic dose reduction, 
cessation, or switch to/prescription of specific antipsychotics; 
however, no convincing evidence supports such strategies,19 
apart from a switch to clozapine when TD is diagnosed 
in patients with schizophrenia and ongoing antipsychotic 
treatment is needed.20,21 Nevertheless, clozapine is not 
easy to use,22 and when clozapine is withdrawn, TD seems 
to recur.23
Several additional treatment approaches for improv-
ing TD symptoms exist that target alternatively proposed 
pathogenetic pathways, such as oxidative stress and impaired 
clearance of phenylalanine, with in some cases very early, 
promising results, such as for branched-chain amino acids, 
ginkgo biloba, vitamin E or melatonin,24–26 but without defini-
tive, large/high-quality trials to support their clinical use. 
In addition, benzodiazepines, non-antipsychotic cat-
echolaminergic agents, gamma-aminobutyric acid agonists, 
cholinergic or anticholinergic agents, or other miscellaneous 
treatments have been tested as augmentation strategies aimed 
at reducing TD severity, with almost no clinically relevant 
improvement27–32 if not detrimental effect, or with tolerability 
issues, such as sedation, ataxia, or risks correlated with 
insulin administration outweighing any potentially beneficial 
effect.29,30,33 Lastly, preliminary evidence suggested relevant 
efficacy and notable safety of deep brain stimulation for TD34 
and of botulinum for focal dystonias.33 A recent compre-
hensive systematic review assessing the quality and level of 
evidence of pharmacological approaches for TD concluded 
that “underpowered trials of limited quality repeatedly fail 
to provide answers.”35
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Beyond stopping or modifying antipsychotic treat-
ment or the aforementioned off-label approaches based 
on preliminary evidence, reversible vesicular monoamine 
transporter-2 (VMAT-2) inhibitors, which block a transporter 
that packages neurotransmitters, particularly dopamine, but 
also noradrenalin, serotonin, and histamine, into presynaptic 
vesicles for release into the synaptic cleft, have been tested 
for TD. Tetrabenzaine was the first VMAT-2 inhibitor that 
was approved in the United States in 2008 for Huntington’s 
chorea and that has been used off-label for the treatment 
of TD,15,36 with promising results from observational 
studies.37 However, serum half-life of tetrabenazine is very 
short, requiring 3 times daily dosing and resulting in large 
peak-to-trough variations in plasma levels that have been 
associated with off-target adverse effects, such as akath-
isia, somnolence, and even depression and suicidality, for 
which a black box warning was required by the US Food 
and Drug Administration (FDA) in subjects suffering from 
Huntington’s chorea.38,39 More recently, 2 novel VMAT-2 
inhibitors, deutetrabenazine and valbenazine,40 have been 
developed, aiming at pharmacokinetic improvements (deu-
tetrabenazine) or pharmacokinetic and pharmacodynamic 
improvements (valbenazine) over tetrabenazine. These 
modifications have resulted in a prolonged half-life and 
reduced peak–trough variations compared to tetrabenazine, 
and, in the case of valbenazine, eliminated enantiomers 
that are responsible for the off-target receptor occupancy 
unrelated to VMAT-2.41,42 Since both deutetrabenazine and 
valbenazine have been tested in double-blind, random-
ized, placebo-controlled trials (DBRPCTs) and were FDA 
approved for the treatment of TD in 2017, and since to our 
knowledge no formal meta-analysis has compared data from 
all available RCTs of VMAT-2-inhibitors, we conducted a 
systematic review and meta-analysis aiming at reporting on 
the meta-analytically derived evidence for the efficacy and 
safety of VMAT-2 inhibitors for the treatment of patients 
with TD. We hypothesized that VMAT-2 inhibitors, pooled 
together and individually, would be superior to placebo in 
the reduction of TD.
Materials and methods
Search strategy and inclusion criteria
An electronic literature search from database inception and 
without language restriction was performed on November 8, 
2017, in the Cochrane library (http://www.cochranelibrary.
com/), PubMed, FDA website (https://www.fda.gov/), and 
ClinicalTrials.gov (https://ClinicalTrials.gov/ct2/home), plus 
relevant conference abstracts. The following search keywords 
were used in PubMed, with equivalent/appropriate syntax 
for other databases: “tardive dyskinesia”[All Fields] AND 
(“tetrabenazine”[All Fields] OR “deutetrabenazine”[All 
Fields] OR “valbenazine”[All Fields]) AND (Review[ptyp] 
OR Clinical Trial[ptyp]). In addition, bibliographies of 
included or relevant references were hand-searched to seek 
further potentially eligible papers. 
Inclusion criteria were: 1) most recent/comprehensive 
systematic review or meta-analysis on VMAT-2 inhibitors 
for TD, with included trials, or 2) individual, open, or ran-
domized trials of VMAT-2 inhibitors for TD. For the formal 
meta-analysis, only data from DBRPCTs in patients with TD 
were considered, and only trials that reported results based 
on the AIMS scale were included.
In addition to the database search, data regarding the 
pharmacodynamic and pharmacokinetic properties of each 
drug were extracted from the official information provided 
by the manufacturers.
Two authors (MS and GP) independently conducted the 
search and selected the eligible papers. Any disagreement 
was resolved by consensus.
Data extraction
Relevant information about efficacy, safety, and clinically 
relevant pharmacokinetic and pharmacodynamic informa-
tion was abstracted from systematic reviews/meta-analyses, 
individual trials, or manufacturer’s drug leaflets. Two authors 
(MS and GP) independently extracted the pharmacokinetic 
and pharmacodynamic properties of each VMAT-2 inhibi-
tor, the number of studies (for reviews), study design, study 
duration, specific drug of interest, continuous and categorical 
efficacy data, and adverse effects frequencies. Any disagree-
ment was resolved by consensus.
Quality assessment
Two authors (MS and GP) independently assessed the quality 
of the included studies with the Cochrane Collaboration’s 
tool for assessing the risk of bias.43
Meta-analysis
We performed a random effects meta-analysis44,45 by using 
comprehensive meta-analysis (CMA, version 2). For continu-
ous variables, we calculated the standardized mean difference 
(SMD) as the primary outcome measure, complemented by 
the weighted mean difference (WMD) whenever the same 
rating scale was used across all trials. For categorical out-
comes, we calculated the risk ratio (RR) and, whenever the 
RR result was statistically significant, the number-needed-to-
treat or harm (NNT or NNH). Effect sizes were accompanied 
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by their 95% confidence intervals (CIs). Heterogeneity was 
assessed with the Cochrane Q and I 2 statistics for each 
analysis (with significant heterogeneity being indicated by a 
p,0.05 or I2$50%, respectively).46 We meta-analyzed each 
VMAT-2 inhibitor separately and also calculated pooled 
effect sizes. Publication bias was assessed via visual inspec-
tion of funnel plots and with the Begg-Mazumdar Kendall’s 
tau47 and Egger bias test.48 In case that publication bias was 
suspected, we calculated the trim and fill adjusted analysis49 
to remove the most extreme small studies from the positive 
side of the funnel plot and recalculated the effect size at 
each iteration until the funnel plot was symmetric around 
the (new/adjusted) effect size. In order to indirectly estimate 
any drug-related difference between VMAT-2 inhibitors, we 
also conducted sensitivity analyses based on the individual 
VMAT-2 inhibitor. In order to have a conservative approach 
and minimize biases, we used a “once randomized-analyzed,” 
or intent-to-treat (ITT) approach for all efficacy and safety 
analyses and ignored the results from the completer analyses. 
The exception was a prespecified modified ITT approach 
in the studies with deutetrabenazine where all eligible and 
consenting subjects were randomized, but a priori only those 
with AIMS scores $6 were analyzed.
Results
Search results
Figure 1 presents the flow diagram of the literature search. 
Our search yielded no article from the Cochrane database 
but 41 individual studies and 3 reviews from PubMed, of 
which 33 were excluded after title/abstract assessment with 
finally 8 published studies and 3 reviews being included 
after full-text assessment. In ClinicalTrials.gov, we iden-
tified 38 trials (DBRPCT and studies with a different 
design), of which 30 were excluded after full assessment 
of each trial results section on the website (with specific 
reasons for the exclusion of each trial reported in detail 
in Table S1). In addition, 2 relevant conference abstracts 
were included.
Different articles reported results from the same trial, or 
from trials not registered in ClinicalTrials.gov (being too 
old), and some trials retrieved in ClinicalTrisls.gov did not 
have related publications. Hence, we merged the information 
gathered from all eligible studies and reviews from PubMed 
with data reported in ClinicalTrials.gov and in conference 
abstracts, and finally included information from 8 distinct 
DBRPCTs, 2 controlled single-blind studies, 7 distinct open-
label studies, and 3 distinct studies with a retrospective or 
case-series design. 
In particular, of these 20 included articles, tetrabenazine 
was evaluated in 2 DBPRCTs (n=10), 1 haloperidol-
controlled RCT (n=13), 1 single-blind placebo-controlled 
study (n=12), 5 open-label studies, and 3 retrospective or 
case-series studies (total n=409). Deutetrabenazine was 
evaluated in 2 DBPRCTs (drug=281, placebo=132) and one 
open label study (n=304). Finally, valbenazine was inves-
tigated in 4 DBRPCs (drug=281, placebo=207) and 1 open 
label study (n=163). Results from all 20 trials and studies 
are summarized in our systematic review. 
Finally, we formally meta-analyzed the 2 DBRPCTs for 
deutetrabenazine (n=413), and 4 DBRPCTs for valbenazine 
(n=488). In addition, the pharmacokinetic characteristics of 
each included VMAT-2 inhibitor were retrieved from the 
specific medication’s package insert sheet.
The main characteristics of the included studies are 
summarized in Table 1. Below, we descriptively summa-
rize the pharmacological properties, clinical indications, 
efficacy, and safety of each drug from individual studies 
(reported in detail in Table 2), quality of included studies 
(Table 3), and a summary of results from meta-analysis 
(Table 4).
Tetrabenazine
Pharmacokinetics and pharmacodynamics
The FDA approved tetrabenazine for Huntington’s disease, 
not TD, in the United States, while the Agenzia Italiana 
del Farmaco approved tetrabenazine for TD in Italy along 
with several other countries including the United Kingdom 
and Canada. Tetrabenazine is composed of a one-to-one 
mixture of two enantiomers, alpha-tetrabenazine and beta-
tetrabenazine. Each enantiomer is metabolized to 2 isomers. 
The (+)alpha and (-)alpha dihydrotetrabenazine (DHTBZ) 
isomers have VMAT-2 reversible inhibitory activity (affinity 
of tetrabenazine for VMAT-2 is Ki ≈100 nM), while the 
(+)beta and (-)beta DHTBZ isomers are weak dopamine 
D2 antagonists (Ki ≈2,100 nM). Tetrabenazine can be 
taken with or without food, and its bioavailability after oral 
administration is $75%, but its half-life is as short as 5 hours 
(thus 3 times daily dosing is required).50 The C
max
 is reached 
within 1–1.5 hours, with blood plasma peaks50 and protein 
binding being close to 85%. Tetrabenazine is extensively 
metabolized by CYP2D6 and 75% of it being eliminated in 
urine and around 16% in feces.
Efficacy
One systematic review of the effects of tetrabenazine for 
TD15 reported results from 12 studies overall, with partially 
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overlapping studies populations,51 with 2 DBRPCTs (n=10), 
1 single-blind placebo-controlled study (n=12), and one halo-
peridol-controlled, randomized study (n=12). Each study had 
very small sample sizes, surprisingly with response rates up to 
100% for tetrabenazine, and all used poor quality assessment 
tools and poor reporting of outcomes, precluding inclusion of 
any of these studies in our meta-analysis. Overall, considering 
also studies with open-label or retrospective design, 
419 patients aged 20–82 years were studied. The study 
duration of the RCTs ranged from 1 to 20 weeks, and the 
tetrabenazine dose ranged between 50 and 150 mg/day. Nota-
bly, in 2 of the RCTs, which were conducted in the 1970s, 
patients had been on antipsychotic treatment (likely all FGAs) 
for .10 years and had been hospitalized for an average of 
Records identified through
database search
(PubMed =41 articles, 3 reviews
Cochrane database =0,
ClinicialTrials.gov =38 trial/studies
conference abstracts =2)
Additional records identified through
other sources
(n=1 trial, from FDA)
Records after duplicates removed:
41 articles, 3 reviews
38 trial/studies results
Records screened:
41 articles, 3 reviews
38 trial/studies results
Records excluded after
title/abstract assessment:
33 articles from PubMed
Full-text articles and trials assessed for
eligibility:
8 articles, 3 reviews
38 trial/studies results
30 trial/studies retrieved in
ClinicialTrials.gov excluded:
4 for deutetrabenazine, 18 for
tetrabenazine, 8 for valbenazine
Included: 8 studies, 3 reviews, with data from
20 trial/studies in the systematic review, of
which 6 trials were meta-analyzed
Tetrabenazine: 1 review article with data from
9 studies and 3 trials; none included in the
meta-analysis
Deutetrabenazine: 2 studies, 1 review,
2 conference abstracts, with data from 2 trials
and 1 open-label study; 2 trials included in
the meta-analysis
Valbenazine: 6 studies and 1 review, with
data from 4 trials and 1 open-label study;
4 trials included in the meta-analysis
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Figure 1 PRISMA flowchart of study selection process.*
Notes: *Different information from the same trial were retrieved from different sources (articles and result section of ClinicalTrials.gov for each trial). Hence, record 
selection flow diagram goes in parallel (articles and trials) with final merging of information from different sources in the present manuscript. Article represents published 
manuscript; study represents trial with design other than DBRPCT, or retrospective data collection; trial represents DBRPCT.
Abbreviation: DBRPCT, double-blind randomized placebo-controlled trial.
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Table 2 Efficacy and safety in trials of VMAT-2 inhibitors for TD*
Study Efficacy Safety/tolerability (AE $5%, serious AE)
Tetrabenazine
Godwin-Austen et al 
(Leung and Breden)15
Randomized, placebo, and 
diazepam-controlled
Sample size =6
Mean change from baseline: PLC -0.5±1.1, diazepam 
-2.2 (1.0), tetrabenazine -3.6±1.6, on 4-point 
severity scale
Most common side effect was sedation, similar to 
sedation after diazepam administration, and 1 case of 
syncope. After tetrabenazine was discontinued, TD 
symptoms relapsed
Kazamatsuri et al52 (Leung 
and Breden)15
Open label
Sample size =24
Remission of TD in 33%, marked reduction 25%, 
none worsened. From 30 oral movements per minute 
at baseline to 10.8 after 6 weeks
Study was discontinued in 4 patients. Parkinsonism was 
not observed
Kazamatsuri et al53 (Leung 
and Breden)15
Randomized, haloperidol-
controlled 
Sample size =13
After 2 weeks, haloperidol showed larger efficacy, 
but at week 12 no patients under haloperidol 
showed remission, while 2 patients on tetrabenazine 
showed remission of dyskinesia. initial improvement 
after 2 weeks generally decreased in both arms 
(tetrabenazine and haloperidol). All dyskinetic 
symptoms relapsed after tetrabenazine discontinuation
NA
Asher et al (Leung and Breden)15
Randomized, placebo-
controlled, cross-over 
Sample size =12
marked response in 33% patients, moderate response 
in 17%, no response in 33%
well tolerated, no behavioral changes observed
Jankovic et al (Leung and Breden)15
Randomized, placebo-
controlled, cross-over 
Sample size =4
All patients improved Adverse effects in 75% of patients: restlessness, drooling, 
gait change, parkinsonism, anxiety
Fahn et al (Leung and Breden)15
Open-label
Sample size =14
Majority of patients (11/14) were considered 
responders
Parkinsonism in all patients except 1
Jankovic et al (Leung and Breden)15
Open-label 
Sample size =47
Score 1 in 6 patients, score 2 in 25 patients, score 3 
in 11 patients, score 4 and 5 in 1 patient, respectively
Ae in .10% were parkinsonism (24%), drowsiness 
(13%), and depression (11%)
Jankovic et al (Leung and Breden)15
Open-label 
Sample size =93
Patients had mostly (89.3%) excellent response at first 
follow-up
Most common side effects: drowsiness/fatigue (36.5%), 
parkinsonism (28.5%), depression (15%), insomnia (11%), 
anxiety (10.3%), akathisia (9.5%), nausea/vomiting (4.8%). 
23% discontinued therapy due to adverse effects
Watson et al (Leung and Breden)15
Case series 
Sample size =23
78% of patients had a score of at least 3 or 4 at 
baseline, and 87% achieved a score of 0 or 1. 
All patients improved from baseline
Adverse effects: drooling in 2 patients, parkinsonism in 
1 patient
Ondo et al54 (Leung and Breden)15
Open-label 
Sample size =20
AiMS motor subset improved by 54.2%, and 
subjective AiMS improved by 60.4%. Marked 
improvement was reported by 11 patients, 
moderate improvement by 6 patients, and mild 
improvement in 2
Parkinsonism was reported by 5 patients, sedation in 
5 patients as well, and 1 elderly patient withdrawn the 
study because of sedation 
Paleacu et al (Leung and Breden)15
Retrospective
Sample size =17
1 patient showed a decrease in CGiC score, 
4 showed no change, and 10 showed increase in 
CGiC score
Most common side effects: somnolence/weakness (6%), 
parkinsonism (2.5%), akathisia (1.7%), depression (1.7%)
Kenney et al80 (Leung 
and Breden)15 
Retrospective 
Sample size =149
Patients maintaining score of 1 or 2 to last follow-up: 
83.5%, 85.7%
Most common side effects: drowsiness (25%), 
parkinsonism (15.4%), akathisia (7.6%), depression (7.6%)
Deutetrabenazine
NCT02195700 – ARM-TD – 
week 12
DBRPCT (Fernandez et al)56
Sample size =69
After 12 weeks, deutetrabenazine improved AiMS 
score vs placebo (p=0.02). Responders were 48.2% 
with deutetrabenazine, 40.4% with placebo according 
to CGiC, and 42.9% vs 29.8% according to PGiC 
(no significant difference in both). No significant 
difference in mCDQ-24 
Any Ae occurred in 48.3% vs 35.6% with placebo. 
Psychiatric Ae rates were not different in 
deutetrabenazine compared with placebo; anxiety 3.4% 
vs 6.8%, depression 1.7% in both groups, and suicidal 
ideation in 0% vs 1.7%. No worsening in parkinsonism. 
No difference on QTc 
(Continued)
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Table 2 (Continued)
Study Efficacy Safety/tolerability (AE $5%, serious AE)
Deutetrabenazine
NCT02291861 – AiM-TD – 
week 12
DBRPCT (Anderson et al)57
Sample size =298
After 12 weeks, deutetrabenazine improved AiMS 
score vs placebo, in a dose-related pattern (24 mg 
[p=0.003] or 36 mg [p=0.001] per day were effective). 
Responder rate according to AIMS (24 mg, 49%, 
p=0.006; 36 mg, 44%, p=0.032) or CGIC (24 mg, 
p=0.014; 36 mg, p=0.059 – trend to significance) was 
higher with deutetrabenazine vs placebo (12% and 
26%, respectively), while no significant difference was 
described as regards PGiC response or mCDQ-24 
score difference
Any Ae occurred with similar rates in deutetrabenazine 
(range 44%–51%) and placebo (47%). No difference in 
depression, somnolence, sedation, or suicidality
NCT02198794 – RiM-TD – 
III – 2017 (Citrome; Anderson 
et al; Anderson et al)42,58,59
At week 54, deutetrabenazine improved AiMS from 
baseline (p=NA), in both patient previously on 
deutetrabenazine and placebo. Responder rate as 
measured by CGiC increased from 58% at week 6 to 
72% at week 54, and from 53% to 59% as measured 
by PGIC (p=NA)
exposure-adjusted incidence rates of Ae were 
comparable or lower than short-term or placebo 
treatments. No cumulative toxicity was observed. 
Anxiety, somnolence, depression, suicidality, akathisia, 
restlessness, sedation, parkinsonism occurred at similar 
frequency to placebo and deutetrabenazine short-term 
treatment; 90% of psychiatric Ae were mild to moderate 
in severity. 2 serious AE (1 attempted suicide), 4 deaths 
after drug withdrawal
Valbenazine
NCT01393600 – week 4
DBRPCT
(Citrome; ClinicalTrials.gov)41,64
After 4 weeks, valbenazine 12.5 mg was not superior 
to placebo on AIMS score mean difference (p=0.6), 
neither was 50 mg (p=0.4); 50 mg was superior 
after excluding data from one site involved in the 
multicenter study (p,0.01). No statistical analysis 
provided for CGi-TD score 
1 case of serious Ae in 12.5 mg group only. Any other 
AE rate reported in placebo (11.4%); valbenazine 12.5 
mg (23.5%), and 50 mg (31.6%). No specific AE occurred 
in .1 patient in either valbenazine dose. No death
NCT01688037 – KiNeCT – 
week 6
DBRPCT (Citrome; FDA)41,67
After 6 weeks, AIMS (p=0.3), CGI-TD (p=0.7), or 
scores did not improve with valbenazine compared 
with placebo. 
See below (KINECT 4) for analysis of safety and 
tolerability in an aggregated larger sample
NCT01733121 – KiNeCT 2 – 
week 6
DBRPCT (Citrome; O’Brien et al; 
ClinicalTrials.gov)41,64,73
After 6 weeks, AIMS (p,0.01), CGI-TD (p,0.01), 
PGIC (p,0.01), scores were improved from 
valbenazine 25 to 75 mg compared with placebo, and 
CGi-TD, PGiC response rates were 66.7% vs 15.9%, 
57.8% vs 31.8% in valbenazine vs placebo (p=NA), 
respectively 
No serious Ae with valbenazine, 2 serious Aes with 
placebo. Any Aes rate was 49% in subjects taking 
valbenazine and 33% in those under placebo. The most 
common AEs were fatigue and headache (each 9.8% 
vs 4.1% in placebo), constipation, and urinary tract 
infection (each 3.9% vs 6.1% in placebo). No clinically 
relevant alterations in laboratory examinations, eCG. 
No relevant variations in psychiatric symptoms were 
noted. No concerns were expressed about suicidal 
ideation, or depression. No parkinsonism or akathisia. 
No death in valbenazine, 1 death with placebo
NCT02274558 – KiNeCT 3 – 
week 6
DBRPCT (Citrome; Kane et al; 
Correll et al; Hauser et al; Factor 
et al)41,68–70,72
After 6 weeks, AiMS score improved in both 
valbenazine 40 and 80 mg compared with placebo 
(p,0.01), while CGi-TD scores improved in both 
valbenazine dose groups compared with placebo 
(p=0.01 both doses) (trend toward significance in 
all iTT population [p=0.06, 80 mg; p=0.07, 40 mg]. 
AIMS response rates were 40% in 80 mg (p,0.001), 
23.8% in 40 mg (p=0.02), 8.7% in placebo. in 
patients with mood disorders, AIMS (p,0.05, 80 
mg; p=0.002, 40 mg) and CGI-TD (p,0.05, 80 mg; 
p=NA, 40 mg) scores improved in a dose-related 
pattern in valbenazine vs placebo, as well as 
response rate according to AIMS (38.5%, NNT =4 
for 80 mg) or CGI-TD (34.6%, NNT =6 for 80 mg) 
criteria (p=NA). 
Any Ae rate was 40.3% in 40 mg, 50.6% in 80 mg 
group, 43.4% in placebo group. Serious Ae: 7.6% 80 mg, 
5.6% 40 mg, 3.9% PLC. The most common AEs were 
somnolence (5.1% 80 mg, 5.6% 40 mg, vs 3.9% placebo), 
akathisia (2.5% 80 mg, 4.2% 40 mg vs 1.3% placebo), and 
dry mouth (0% 80 mg, 6.9% 40 mg, vs 1.3% placebo). 
1 patient died in 80 mg group. worsening of suicidal 
ideation rates did not differ from placebo (1.3% 80 
mg, 4.2% 40 mg, vs 5.3% PLC). No relevant laboratory 
alteration 
(Continued)
Drug Design, Development and Therapy 2018:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1224
Solmi et al
Table 2 (Continued)
Study Efficacy Safety/tolerability (AE $5%, serious AE)
Valbenazine
in patients with schizophrenia or schizoaffective 
disorder, AIMS (p,0.01 for both doses) and CGi-TD 
(p=NA) scores improved in a dose-related pattern 
in valbenazine vs placebo, as well as response rates 
according to AIMS (40.9%, NNT =4 for 80 mg) or 
CGI-TD criteria (29.5%, NNT =17 for 80 mg) (p=NA)
NCT02405091 – KiNeCT, 
KiNeCT 3, KiNeCT 4 – week 48
OL (Factor et al; Kane et al; 
Josiassen et al; Correl et al)69–72
in both patients with mood disorders and 
schizophrenia/schizoaffective disorder AiMS and 
CGi-TD scores, valbenazine showed continued and 
progressive improvement from baseline to week 48, 
with return toward baseline values at week 52 after 
valbenazine discontinuation (p=NA). At week 48, 
response rates showed the same improvement with a 
dose-related pattern, according to AIMS (56%, 80 mg) 
or CGI-TD (80%, 80 mg) criteria in mood disorders, 
and (50%, 80 mg) or (73.7%, 80 mg) in patients with 
schizophrenia (p=NA)
Data from KINECT (n=46), KINECT 3 (n=220), and 
KINECT 4 (n=164) were pooled in 430 subjects, and 
Ae reported at week 48. Any TeAe rate was 66.5%, 
with 14.7% discontinuation due to Ae. TeAe rate was 
64.4% in schizophrenia/schizoaffective disorder and 
71.9% in mood disorders. The most common Aes in 
schizophrenia/schizoaffective were urinary tract infection 
(6.1%), headache (5.8%), and somnolence (5.2%). The 
most common Aes in mood disorders were headache 
(12.4%), urinary tract infections (10.7%), and somnolence 
(9.1%). Psychiatric symptoms did not change with the 
administration of valbenazine, according to PANSS, CDSS, 
MADRS, and YMRS scales in both diagnostic groups. 
Suicidal ideation rate in patients under valbenazine was 
5%, similar to that with placebo in KINECT 3 (5.3%). 
extrapyramidal symptoms were minimal. Rare, minimal, 
and non-clinically significant alterations were noted in 
laboratory parameters and eCG 
Note: *Data adapted and expanded from Leung and Breden.15
Abbreviations: AE, adverse event; AIMS, Abnormal Involuntary Movement Scale; CGI, Clinical Global Impression; mCDQ, modified Craniocervical Dystonia Questionnaire; NA, not 
assessed; PGiC, Patient’s Global impression of Change; TD, tardive dyskinesia; TeAe, treatment-emergent adverse event; vMAT, vesicular monoamine transporter; PANSS, Positive 
and Negative Syndrome Scale; CDSS, Calgary Depression Scale for Schizophrenia; MADRS, Montgomery and Asberg Depression Rating Scale; YMRS, Young Mania Rating Scale.
Table 3 Risk of bias in randomized blinded trials comparing valbenazine or deutetrabenazine versus placebo for tardive dyskinesia
Drug (study) Trial Adequate 
sequence 
generation
Allocation 
concealment
Blinding 
(participants 
and 
personnel)
Blinding 
(outcome 
assessment)
Incomplete 
outcome 
data 
addressed
Free of 
selective 
reporting
Free of 
other 
bias
Summary 
assessment
Deutetrabenazine
(Anderson et al)57
NCT02291861 – 
AiM-TD
Low Low Low Low Low Low Low Low
Deutetrabenazine
(Fernandez et al)56
NCT02195700 – 
ARM-TD
Low Low Low Low Low Low Low Low
valbenazine
(FDA)39
NCT01688037 – 
KiNeCT 
Low Low Low Low Low Low Low Low
valbenazine
(Citrome; O’Brien 
et al; ClinicalTrials.
gov)41,64,73
NCT01733121 – 
KiNeCT 2
Low Low Low Low Low Low Low Low
valbenazine
(Citrome; Correll 
et al; Hauser et al; 
Kane et al)41,68,69,72
NCT02274558 – 
KiNeCT 3
Low Low Low Low Low Low Low Low
valbenazine
(ClinicalTrials.
gov)64
NCT01393600 Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Summary 5 out of 6 DBRPCT had low risk of bias; it was not possible to collect information for one trial
29 years.52,53 Moreover, in just 1 trial, tetrabenazine was 
compared with an active control intervention, namely, 
haloperidol, without showing a benefit in TD reduction 
versus haloperidol.53 In one prospective, single-blind trial,52 
dyskinesia “disappeared” in 1 out of 3 patients, “improved” 
in 1 out of 4 patients, and the average oral movements 
per minute significantly decreased from baseline and then 
re-increased to baseline values after tetrabenazine cessation.52 
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In a more “recent,” single-blind, randomized trial (published 
in 1999),54 all patients reported at least mild improvement, 
and dyskinesia clearly improved from baseline.
Overall, there is a lack of high-quality double-blind 
randomized, placebo controlled RCTs, without convinc-
ing evidence of efficacy of tetrabenazine for TD. No “head 
to head” double-blind comparison with another VMAT-2 
inhibitors has been performed.
Safety and tolerability
Most of the safety data come from trials targeting condi-
tions other than TD (eg, Huntington’s disease). Gener-
ally, almost 9 out of 10 patients experienced $1 adverse 
effect during tetrabenazine treatment. In patients with 
TD, the most frequent adverse events (AEs) (.10% 
and .5% more frequent than placebo) were drowsiness 
(mean: 24.8%, range: 13%–36.5%), sedation/somnolence 
(mean: 18.5%, range: 6%–31%), parkinsonian side effects 
(mean: 11.9%, range: 4.3%–78.6%), insomnia (11%), anxiety 
(10.3%), depression (mean: 6.8%, range: 1.7%–11%), and 
akathisia (mean: 6.3%, range: 1.7%–9.5%). Sedation and 
acute motor syndromes (parkinsonian side effects, dystonic 
reaction, and akathisia), which can be due to D2 antagonism 
of the beta-isomers of tetrabenazine, have been reported in 
approximately 1 out of 4 patients.54 Also, based on data in 
Huntington’s disease, tetrabenazine has a black box warning 
for depression and suicidality,39 leading to the recommenda-
tion that attention should be paid to mood status or aberrant 
acting out behavior during tetrabenazine treatment. Somno-
lence and sedation may impair driving abilities. QT prolonga-
tion may occur, but does not seem to be clinically relevant. 
Dysphagia can also occur, increasing the risk of pneumonia. 
Hyperprolactinemia may occur as well. Notably, in the trials 
included in the abovementioned systematic review,15 specifi-
cally targeting TD, 1 patient out of 24 did not complete the 
study due to psychotic exacerbation.52 
Poor metabolizers, special populations, 
and concomitant drugs 
As per FDA labeling, tetrabenazine dose should not exceed 
50 mg/day in poor CYP2D6 metabolizers, or 100 mg/day 
in extensive metabolizers, yet no clear correlation has 
been demonstrated between CYP2D6 status and clinical 
response.55 Guidance from labels in other countries may 
differ. Tetrabenazine is contraindicated in patients with any 
degree of hepatic impairment, and in patients with suicidal 
ideation, or untreated/inadequately treated depression. 
Pregnant or lactating women should be warned that data from 
animal studies suggest possible fetal harm but that no data are 
available from human studies. The tetrabenazine dose should 
be decreased in case of co-treatment with CYP2D6 inhibi-
tors (eg, paroxetine and fluoxetine), and tetrabenazine must 
not be co-administered with monoamine oxidase inhibitors 
(MAOIs) or reserpine (an irreversible VMAT inhibitor), due 
to possible toxicity related to partially overlapping pharma-
codynamic actions. No efficacy or safety data are available 
for pediatric or geriatric populations.
Deutetrabenazine
Pharmacokinetics and pharmacodynamics
Deutetrabenazine is a reversible VMAT-2 inhibitor. Similar 
to tetrabenazine, there are α and β enantiomers, and each 
gives rise to 2 isomers of a DHTBZ metabolite. However, the 
incorporation of deuterium, which is a stable, non-radioactive, 
non-toxic, and naturally occurring isotope of hydrogen, in 
place of hydrogen at the sites of primary metabolism results 
in slower metabolic clearance compared to tetrabenazine and 
lower Cmax values, despite similar effective doses as used 
in the tetrabenazine trials (36–48 mg). Deutetrabenazine 
should be taken with food and its bioavailability after oral 
administration is $80%. The half-life of deutetrabenazine 
is about 9–10 hours (thus twice-daily dosing is required),1 
and its protein binding is close to 84%. Deutetrabenazine is 
extensively metabolized by CYP2D6, with minor contribu-
tions from CYP1A2 and CYP3A4/5, and 80% of it being 
eliminated in urine and around 10% in feces. 
Efficacy
One systematic review reported results from 2 acute trials 
and 1 open-label, long-term study.42 In 2017, the US FDA 
approved deutetrabenazine for both Huntington’s disease and 
TD. One multicenter DBRPCT (“ARM-TD study”) included 
117 (deutetrabenazine =58, placebo =59) patients with moder-
ate to severe TD (82.9% of which with AIMS $6 based on 
blinded video assessment), and assessed AIMS, clinician’s 
and patient’s global impression (CGI and PGI) scores after 12 
weeks. Patients were administered deutetrabenazine starting 
from 12 mg/day, with weekly increases of 6 mg up to 48 mg 
maximum (36 mg for patients taking strong CYP2D6 inhibi-
tors), according to clinical response. Baseline AIMS values 
were 9.6 (4.1 SD) with deutetrabenazine and 9.6 (3.8 SD) with 
placebo. Although no significant difference was noted in CGI 
scores compared with placebo at study endpoint, or in modi-
fied Craniocervical Dystonia Questionnaire (mCDQ-24) (p 
not available for both comparisons), AIMS scores improved 
significantly more with deutetrabenazine than placebo (place-
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bo-subtracted treatment difference -1.4, standard error [SE]: 
0.6, p=0.019).56 Another multicenter DBRPCT (“AIM-TD 
study”) included 298 patients (deutetrabenazine =224 divided 
in 3 groups: 12, 24, and 36 mg/day; placebo =74) with TD 
(AIMS $6) duration $3 months, and assessed AIMS after 
12 weeks (or at least at 1 follow-up observation).57 Baseline 
AIMS values were 9.6 (2.4 SD) with 12 mg/day deutetra-
benazine, 9.4 (2.9 SD) with 24 mg/day, 10.1 (3.2 SD) with 
36 mg/day, and 9.5 (2.7 SD) with placebo. Efficacy was 
demonstrated compared with placebo for deutetrabenazine 
36 mg/day (placebo-subtracted treatment difference -1.9, 
SE: 0.58, p=0.001) and 24 mg/day (-1.8, SE: 0.60, p=0.003), 
but not for 12 mg/day (-0.7, SE: 0.57, p=0.217). Moreover, 
compared to placebo (12%), the proportion of patients with 
a $50% AIMS score reduction was significantly higher 
with deutetrabenazine 24 mg/day (35%, OR =3.96, 95% 
CI =1.46, 10.72, p=0.005) and 36 mg/day (33%, OR =3.80, 
95% CI =1.40, 10.36, p=0.007). Conversely, in the ITT 
population, deutetrabenazine did not differ significantly 
from placebo regarding the Patient Global Impression of 
Change (PGIC) defined responder rate (12 mg/day: p=0.37, 
24 mg/day: p=0.13, 36 mg/day: p=0.30) or mCDQ-24 
scores (12 mg/day: p=0.66, 24 mg/day: p=0.24, 36 mg/day: 
p=0.12).57 In the OLE study58,59 (59 weeks, ongoing, n=304 
from the ARM-TD and AIM-TD studies), all efficacy mea-
sures (continuous scores or responder rates) continued to 
improve from week 6 to week 54. No head to head comparison 
with other VMAT-2 inhibitors has been performed.
Safety and tolerability
Deutetrabenazine was generally well tolerated, with trial 
completion rate ranging from 89% to 95% in DBRPCTs,41 and 
the NNH for all-cause discontinuation was not significantly 
different from placebo.41 Moreover, deutetrabenazine had 
similar AEs rates in all dose arms compared with placebo (36 
mg/day: 51.4%; 24 mg/day: 43.8%; 12 mg/day: 48.6%; pla-
cebo: 47.2%), with the 36 mg/day dose being associated with 
the highest frequency of AEs.57 Moreover, no worsening of 
EPS occurred,56 yet such a definition should be replaced with 
finer definitions of specific adverse motor events, with con-
sistent reporting of rates of each of them in RCTs.60 Sedation/
somnolence may occur with deutetrabenazine, but the manu-
facturer correctly advises that patients with Huntington’s 
disease should be advised about such a risk, while there 
is no such need in patients with TD, given the comparable 
rates of somnolence in the deutetrabenazine (2%–13.8%) 
and placebo group (4%–10.2%). Although deutetrabenazine, 
like tetrabenazine, has a black box warning for depression 
and suicidality in patients with Huntington’s disease (based 
on data from trials in this population), data from 2 trials in 
patients with TD did not show any increased risk versus pla-
cebo, which is why deutetrabenazine did not receive such a 
regulatory warning for the TD population.56 In the ARM-TD 
trial, depressed mood/depression was noted at the exact same 
frequency as placebo (1.7%), with no patients reporting 
suicidality.56 In the AIM-TD trial, suicidality was reported in 
the 24 and 36 mg/day arms (2.7% the highest),57 but without 
any difference from placebo. Also, in the long-term, OLE 
study, deutetrabenazine showed42,58,59 similar adjusted inci-
dences of AEs, compared with both the acute-phase trials 
and the placebo. Moreover, .90% of psychiatric AEs were 
mild to moderate. Hence, the absence of any FDA warning 
about a putative increased risk of depression or suicide in 
patients with TD seems appropriate, at least in the included 
psychiatrically stable patients with TD. Deutetrabenazine has 
not been tested in the pediatric population.
Poor metabolizers, special populations, 
and concomitant drugs 
Poor CYP2D6 should be prescribed lower deutetrabenazine 
doses. No data are available about deutetrabenazine in 
patients with renal impairment. Even if no data are available, 
based on data for tetrabenazine, lower doses should be con-
sidered when hepatic function is impaired. Deutetrabenazine 
dose should also be decreased in the presence of CYP2D6 
inhibitors (eg, paroxetine and fluoxetine). However, since 
the slower metabolism and lower Cmax reduce the impact 
of slow CYP2D6 metabolizers, no genotyping has been 
recommended, unlike for tetrabenazine.
valbenazine
Pharmacokinetics and pharmacodynamics
Valbenazine is a highly selective, reversible VMAT-2 inhibi-
tor that consists of the (+)α-DHTBZ enantiomer, an oxida-
tive metabolite of valbenazine, and its 2 isomers, with all 3 
molecules having VMAT-2 binding only.61 It can be taken 
with or without food, although the C
max
 is decreased by high-
fat meals. Oral bioavailability of valbenazine is ~49%, its 
half-life is about 20 hours,62 enabling once daily dosing, t
max
 
is between 0.5 and 1.0 hours,62 steady state is reached within 
8 days,62 and protein binding is 99%. Area under the curve 
(AUC) analyses have shown a dose-proportional increase 
from 50 to 150 mg/day and more than dose-proportion from 
1 to 50 mg/day.62 
The affinity of valbenazine for VMAT-2 is Ki ≈150 nM, 
with virtually no affinity for VMAT-1 (Ki .10,000 nM). 
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Valbenazine and its metabolites do not have any affinity for 
other than VMAT-2 targets, namely, serotonin, dopamine, 
adrenergic, histaminergic, or muscarinic receptors, thus 
minimizing untoward effects beyond those specifically 
linked to its specific binding site. It is extensively metabo-
lized by hydrolysis and oxidative metabolism (CYP3A4/5); 
(+)-α-HTBZ seems to be further metabolized in part by 
CYP2D6. Approximately 60% of elimination takes place in 
urine and 30% in feces.
Efficacy 
The US FDA approved valbenazine for TD in 2017.63 
One systematic review41 has identified 6 completed trials 
(2 long-term extension studies and 4 DBRPCTs), includ-
ing a total of 660 subjects, aged 18–85 years, with a study 
duration ranging from 12 days to 48 weeks, and with the 
valbenazine dose ranging from 12.5 to 100 mg/day. Four 
double-blind trials (NCT01393600,64 KINECT, KINECT 2, 
and KINECT 3)41,65–73 and 1 dose-blind extension study 
(KINECT 4)41,69–72 reported on the efficacy and safety of 
valbenazine,41,68–73 in patients who developed TD during 
antipsychotic treatment for schizophrenia, schizoaffective 
disorder, or mood disorders, or during metoclopramide treat-
ment for a gastrointestinal conditions. 
Baseline AIMS scores in KINECT 2 were 8.0 (3.5 SD) in 
the valbenazine and 7.9 (4.5 SD) in the placebo group, being 
10.4 (3.6) for 80 mg/day, 9.7 (4.1 SD) for 40 mg/day, and 
9.9 (4.3 SD) for placebo in the KINECT 3 study. 
Although valbenazine did not separate from placebo 
in the small dose-finding studies NCT01393600 (4 weeks, 
37 patients in a blinded cross-over study, analyzed: 
drug =32, placebo =33) and KINECT (6 weeks, drug =50, 
placebo =54),41,64–67 it showed significantly greater improve-
ment in the AIMS total score compared to placebo at week 
6 in 2 larger, acute-phase KINECT 2 (6 weeks, valbenazine: 
n=45, placebo n=44), and KINECT 3 trials (6 weeks, val-
benazine: n=151, placebo: n=76, with extension to 48 weeks: 
n=198).68,70,73 In KINECT 2, improvement in total AIMS 
scores were consistently higher with valbenazine than pla-
cebo (treatment difference -2.4, SE: 0.7, p,0.001), as well as 
CGI-TD score (treatment difference -0.8, SE: 0.2, p,0.001). 
The same was true in KINECT 3 with regard to the AIMS 
score change (80 mg/day: -3.2, SE: 0.4, p,0.001; 40 mg/
day: -1.9, SE: 0.4, p,0.001, vs placebo -0.1, SE: 0.4).
Valbenazine also outperformed placebo in response 
rates, regardless of the definition of response. For example, 
in KINECT 2, a $50% AIMS total score reduction was 
observed in 48.9% with valbenazine versus 18.2% with 
placebo ( p,0.001), with rates of patients achieving a 
CGI-TD #2 (ie, “much or very much improved”) being 
67% with valbenazine and 16% with placebo (p,0.001).41 
Similarly, in KINECT 3, a $50% AIMS total score reduc-
tion was observed in 40.0% with valbenazine 80 mg/day 
(p,0.001), 23.8% with 40 mg/day (p=0.02), and 8.7% with 
placebo, with the 80 mg/day dose consistently showing the 
highest response rates.41,68–73 Notably, the same efficacy and 
dose-related profile was confirmed in both the schizophrenia 
and schizoaffective disorder subgroup,69 as well as the mood 
disorder subgroup.72
The NNT for treatment response was consistently around 
4 for valbenazine 80 mg daily, ranging from 2 to 9, with 
doses from 25 to 75 mg/day. In KINECT 3, the NNT for the 
AIMS-based response in all patients was 4 for 80 mg/day 
and 7 for 40 mg/day, being consistent in patients with mood 
disorders and schizophrenia/schizoaffective disorder (mood 
disorder subgroup: 80 mg/day: NNT =4 for AIMS-based 
definition and NNT =6 for CGI-TD, 40 mg/day: NNT =9 for 
AIMS and NNT =8 for CGI-TD; schizophrenia subgroup: 
80 mg/day: NNT =4 for AIMS-based definition and NNT =17 
for CGI-TD, 40 mg/day: NNT =6 for AIMS and NNT =10 
for CGI-TD).41,61,68,69,72 
In exploratory analyses, statistical separation of val-
benazine from placebo occurred as early as week 2 at 
80 mg/day and did not differ according to sex, age, ethnicity, 
underlying main diagnosis, or TD baseline severity.68,73 
However, in KINECT 2, the PGIC-based (treatment suc-
cess) response rate statistics were not reported, only showing 
numerically higher rates with valbenazine versus placebo 
(57.8% vs 31.8%, p=NA),73 and in KINECT 3, the endpoint 
CGI-TD score differences missed statistical significance 
(treatment difference -0.3, SE: 0.1, p=0.074).68 
In the OLE study (48 weeks, plus 4 weeks after val-
benazine withdrawal, n=164), all efficacy measures (con-
tinuous scores or responder rates) continued to improve 
from week 6 to week 48, but then worsened until week 52 
after valbenazine was discontinued, trending back to the 
acute baseline values, supporting the need for continuation 
treatment.69,70,72 
No “head to head” comparison with other VMAT-2 
inhibitors or other agents has been performed.
Safety and tolerability
Valbenazine was generally well tolerated,41 with compa-
rable study completion rates on valbenazine and placebo 
(KINECT 2: valbenazine: 76%, placebo: 80%; KINECT 3: val-
benazine 80 mg/day: 88.8%, valbenazine 40 mg/day: 82.9%, 
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placebo: 91%). Furthermore, no detrimental effects were 
noted on core psychopathologic symptoms of the underly-
ing mental condition,41 in both the acute and the long-term 
extension trials.71 In addition, there was no increase in sui-
cidal behavior or depression noted, at least in the included 
psychiatrically stable patients. Calgary Depression Scale 
for Schizophrenia and Montgomery and Asberg Depression 
Rating Scale scores remained stable after treatment with 
valbenazine 40 and 80 mg/day in both the 6-week KINECT 
3 trial68 and the KINECT 4 long-term tolerability trial.71 
Two potential tolerability concerns have been reported,41 
namely, QTc prolongation and somnolence. However, QTc 
prolongation, which was modeled by the FDA, was not clini-
cally relevant at regular doses74 and should be monitored par-
ticularly in those with QTc prolongation or other arrhythmias 
associated with QT prolongation. Nevertheless, no clinically 
relevant ECG alteration was noted in the acute 6-week and 
48-week long-term trials.41,71 Moreover, although patients 
with TD experienced numerically higher rates of somnolence 
compared with placebo (KINECT 2: valbenazine: 5.9%, pla-
cebo: 2%, p=NA; KINECT 3: valbenazine: 5.3%, placebo: 
3.9%, p=NA), the rates were very low. Interestingly, in all 
patients, decreased appetite was reported more frequently 
with valbenazine versus placebo (KINECT 2: valbenazine: 
7.8%, placebo: 0%).73 
The most frequent long-term AEs in both schizophre-
nia/schizoaffective and mood disorder subsamples in the 
48-week extension study were somnolence, urinary tract 
infections, and headache.71 Finally, a potential risk of dose-
related prolactin, bilirubin, and alkaline phosphatase increase 
was noted as per the FDA evaluation, but was not observed in 
the acute trials, and no clinically relevant laboratory alteration 
was noted in the 48-week, long-term tolerability trial.71
Poor metabolizers, special populations, 
and concomitant drugs 
Lower doses (ie, 40 mg/day) should be prescribed in patients 
with known slow CYP2D6 metabolizer status or intolerability 
to 80 mg/day.41 Patients with moderate to severe hepatic 
impairment should take the lower dose of valbenazine, and 
pregnant or lactating women should be advised of the poten-
tial risk for the fetus or newborn, even if no data about such 
risks in humans are available to date. As for renal impairment, 
no dose adjustment is required for mild to moderate renal 
impairment, while valbenazine should be avoided in case of 
severe renal failure since no data are available.41 
No dose adjustment is required in the elderly popula-
tion, and no efficacy or safety data are currently available 
for pediatric populations.41 Valbenazine should not be 
prescribed with MAOIs, or strong CYP3A4 inducers (eg, 
carbamazepine, St John’s wort, phenytoin, and rifampin) and 
should be prescribed at a reduced dose when given together 
with strong inhibitors of CYP2D6 (eg, paroxetine, fluoxetine, 
and quinidine) or CYP3A4 (eg, itraconazole, ketoconazole, 
and clarithromycin), and digoxin concentrations should be 
monitored when valbenazine is administered with digoxin, 
due to possible increase of blood levels of digoxin with 
concomitant administration.41 However, no genotyping has 
been recommended unlike for tetrabenazine. In the 48-week, 
long-term tolerability trial, no relevant interaction with ongo-
ing concomitant medications was reported.71
Quality of included studies
Table 3 reports the quality of included studies. According 
to the Cochrane Risk of Bias Tool, 5 out of 6 blinded tri-
als had low risk of bias, while for 1 (NCT01393600), no 
detailed methodological information was available (unclear 
risk of bias).
Meta-analysis
Meta-analyses were performed for AIMS change (pri-
mary outcome), CGI-TD change, mCDQ-24 change, and 
treatment response based on AIMS ($50% total score 
reduction), CGI-TD (score #2, “much improved” or “very 
much improved”), or PGI-C (“treatment success”). Table 4 
summarizes the results of random effects meta-analysis for 
VMAT-2 inhibitors pooled together and for deutetrabenazine 
and valbenazine individually, and Figure 2 presents the forest 
plot of AIMS change. All other forest plots and funnel plots 
of meta-analyses are available upon request.
Results confirmed the efficacy of VMAT-2 inhibitors 
for TD. AIMS scores reduced significantly more with 
VMAT-2 inhibitors as a class than placebo (trial arms 
k=8; SMD =-0.46, 95% CI =-0.28, -0.64, p,0.001; 
WMD =-1.67, 95% CI =-1.07, -2.27; p,0.001; I2=21%) 
and with both deutetrabenazine (k=4; SMD =-0.40, 
95% CI =-0.19, -0.62, p,0.001; WMD =-1.43, 95% 
CI =-0.67, -2,19; p,0.001; I2=0%) and valbenazine 
(k=4; SMD =-0.58, 95% CI =-0.26, -0.91, p,0.001; 
WMD =-2.07; 95% CI =-1.08, -3.05; p,0.001; I2=50%) 
individually. VMAT-2 inhibitors as a class were superior for 
treatment response, defined according to AIMS ($50% of 
AIMS score improvement from baseline) (k=8; RR =2.66; 
95% CI =1.77, 3.99, p,0.001; I2=0%; NNT =5, 95% 
CI =4, 8, p,0.001). The same was true for deutetrabenazine 
(k=3; RR =2.13; 95% CI =1.10, 4.12; p=0.024; I2=0%; 
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NNT =7, 95% CI =3, 333, p=0.046), and valbenazine (k=5; 
RR =3.05; 95% CI =1.81, 5.11; p,0.001; I2=0%; NNT =4, 
95% CI =3, 6, p,0.001) individually. Similar results were 
found for VMAT-2 inhibitors as a class pertaining to 
response defined according to CGI criteria (k=9; RR =1.50; 
95% CI =1.14, 1.97; p=0.003; I2=44.32%; NNT =6, 95% 
CI =3, 18, p=0.004), with consistent results for valbenazine 
(k=5; RR =2.06, 95% CI =1.24, 3.41; p=0.005; I2=59.96%; 
NNT =5, 95% CI =3, 62, p=0.034), while deutetrabenazine 
showed only a trend toward significance (k=4; RR =1.32; 
95% CI =0.96,1.82; p=0.088; I2=0%; NNT =9, 95% CI =4, 
200, p=0.041). 
Deutetrabenazine and valbenazine were not significantly 
superior to placebo regarding the following secondary out-
comes for which results were only available for one or the 
other VMAT-2 inhibitor. Deutetrabenazine: mCDQ-24 (k=4; 
p=0.157) and PGI-C response (k=4; p=0.149); valbenazine: 
CGI-TD scores change (k=6; p=0.953). Notably, when 12 mg 
group in AIM-TD trial was removed from analyses, a trend 
toward a significant improvement in mCDQ-24 appeared 
(p=0.079). Also, when deutetrabenazine 12 mg arm was 
removed from analyses, heterogeneity significantly dropped 
across the above-described analyses.
With regard to safety, a meta-analysis was performed 
for all adverse effects reported in the included data sources, 
and all results are reported in Table 5. No increased risk of 
AEs versus placebo emerged with VMAT-2 inhibitors as 
a class or with deutetrabenazine or valbenazine individu-
ally. This non-differential adverse effect risk included no 
increased risk of depression, suicidal ideation, sedation, 
or somnolence, which had been a concern with tetra-
benazine (but whose data could not be meta-analyzed due 
to insufficient trial design). In fact, VMAT-2 inhibitors 
were associated with a significantly lower risk of nausea 
compared with placebo (k=4, RR =0.31, 95% CI =0.10, 
0.95, p=0.04).
Discussion
Tetrabenazine, deutetrabenazine, and valbenazine inhibit 
VMAT-2 action, resulting in less dopamine being transported 
from the cytoplasm into presynaptic vesicles, which leads to 
less dopamine release from the pre-synaptic neurons into the 
synaptic cleft.36 This reduced dopamine release results in less 
stimulation of post-synaptic dopamine receptors in the nigro-
striatal pathway, which is thought to subsequently decrease 
dyskinetic movements. Despite this common mechanism of 
action, pharmacological factors, efficacy, and safety should 
be considered when selecting a VMAT-2 inhibitor to treat 
TD, since any preference of one VMAT-2 inhibitor over 
another is currently based on individual medication proper-
ties, rather than on head-to-head comparison trials, which 
are still lacking. 
Results of this systematic review and meta-analysis 
indicate that high-quality evidence for the efficacy and 
Statistics for each study
Random effect meta-analysis of AIMS change
NCT02195700
ARM-TD 12–48 mg
NCT02291861
AIM-TD 12 mg
NCT02291861
AIM-TD 24 mg
NCT02291861
AIM-TD 36 mg
NCT01688037
KINECT 50–100 mg
NCT01733121
KINECT 2 25–75 mg
NCT02274558
KINECT 3 40 mg
NCT02274558
KINECT 3 80 mg
Study name
Lower
limit
–0.775
–0.649
–0.931
–0.990
–0.616
–0.552
–1.122
–0.958
–1.345
–0.908
–0.636
Upper
limit
–0.036
0.258
–0.015
–0.073
–0.186
0.208
–0.267
–0.155
–0.534
–0.360
–0.278
Z-value
–2.153
–0.846
–2.024
–2.271
–3.662
–0.888
–3.181
–2.714
–4.544
–3.536
–5.006
–0.406
Std diff
in means
–0.196
–0.473
–0.531
–0.401
–0.172
–0.604
–0.556
–0.939
–0.584
–0.457
p-value
0.031
0.397
0.043
0.023
0.000
0.374
0.001
0.007
0.000
0.000
0.000
Standard
error
0.188
0.231
0.234
0.234
0.100
0.194
0.218
0.206
0.207
0.165
0.091
Variance
0.036
0.054
0.055
0.055
0.012
0.038
0.048
0.042
0.043
0.027
0.008
Deutetrabenazine
Group by drug
Deutetrabenazine
Deutetrabenazine
Deutetrabenazine
Deutetrabenazine
Valbenazine
Valbenazine
Valbenazine
Valbenazine
Valbenazine
Overall
Reference
57
56
57
57
41, 67
41, 64, 73
41, 68, 69, 70, 72
41, 68, 69, 70, 72
–2.00
VMAT 2 inhibitors Placebo
–1.00 0.00 1.00 2.00
Std diff in means and 95% CI
Figure 2 Forest plot of AiMS change after treatment with deutetrabenazine and valbenazine.
Abbreviation: AiMS, Abnormal involuntary Movement Scale.
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safety in patients with TD exists for the 2 FDA-approved 
VMAT-2 inhibitors, deutetrabenazine and valbenazine, but 
not for tetrabenazine. Furthermore, pharmacokinetic and 
also pharmacodynamic properties of VMAT-2 inhibitors 
differ. Tetrabenazine has a short half-life, needs to be given 
3 times daily, leading to high peak levels and high peak–
trough variations that seem to be responsible for off-target 
adverse effects, such as sedation/somnolence, acute motor 
syndromes, including parkinsonism and akathisia, QTc 
prolongation, and, possibly, depression and suicidality.15 
In contrast, deutetrabenazine has a longer half-life, can be 
given twice daily and has less peak levels and peak–trough 
variation, which reduces its adverse effect risk, although it 
still gives rise to 4 active metabolites, 2 of which have weak 
dopamine receptor blocking properties.42 Valbenazine, on the 
other hand, has an even longer half-life, can be given once 
daily and is metabolized to +-(α)HTBZ with its 2 isomers, 
which each have highly selective VMAT-2 activity.41
Regarding efficacy, both deutetrabenazine and valbenazine 
have demonstrated robust efficacy for the reduction of AIMS 
scores and, regarding treatment response,41,42,56–59,64,68–73 
generally with higher doses producing greater efficacy and 
with medium effect sizes and clinically relevant NNTs of 
2–9 for variously defined treatment response. In contrast to 
clinician-rated outcomes, patient-rated outcomes were less 
robust or nonsignificant. However, this reduced the ability to 
demonstrate superiority compared to placebo on patient-rated 
outcomes may have to do with the fact that not all patients 
are fully aware of the presence or impact of the TD.75–79 
In this context, data are missing that put the efficacy results 
into the context of patient awareness and burden caused by 
the TD, such as in subgroup analyses. To comprehensively 
assess the impact of TD and of treatments for TD, the field 
will have to define TD-specific rating scales that tap into 
the subjective and functional relevance of TD that may not 
necessarily be directly related to total TD severity, but also 
(rather) to local body area distribution and the functional 
impact of the abnormal involuntary movements. 
Moreover, since, like with clozapine,23 discontinuation of 
valbenazine was associated with a general recurrence of TD, 
even after 48 weeks of treatment,59,71 it will be important to 
clarify if there is a subgroup of patients in whom TD does not 
recur after remission during VMAT-2 inhibitor treatment, be 
it those in whom dopamine blocking agents could be stopped, 
or in those with a short duration or milder or locally more 
limited forms of TD. Notably, effects of discontinuation have 
not yet been studied with deutetrabenazine, while observa-
tional studies have shown TD recurrence after withdrawal 
of tetrabenazine.37,80 Moreover, data are missing that could 
help to determine if starting a VMAT-2 inhibitor in patients 
with only subtle dyskinetic movements that are still below 
the threshold of Schooler–Kane criteria81 can effectively 
prevent progression to TD.
Different from tetrabenazine, the safety and tolerability of 
deutetrabenazine and valbenazine was very good. There was 
no increased treatment discontinuation versus placebo and 
no decrease in efficacy of the antipsychotics for the under-
lying psychiatric condition. Moreover, the QTc prolonging 
effects of VMAT-2 inhibitors seemed modest.68,71 Similarly, 
in patients with TD, parkinsonian side effects, akathisia, 
and somnolence/sedation were far less common with either 
deutetrabenazine (parkinsonian side effects: 0%–1%; 
akathisia: 0%–5.2%; sedation/somnolence: 0%–13.8%) or 
valbenazine (parkinsonian side effects: 0%–3.8%; akathisia: 
0%–5.3%; sedation/somnolence: 0%–5.9%) than with tetra-
benazine (parkinsonian side effects: 4.3%–78.6%; akathisia: 
1.7%–9.5%; sedation/somnolence: 6%–31%), despite ongo-
ing treatment with antipsychotics.
Importantly, due to results from studies in patients with, 
tetrabenazine has a black box warning for depression and 
suicidality. Based on the limited data in TD patients, tetra-
benazine was still associated with depression in 6.8% (range 
1.7%–11%) of patients. Conversely, neither depression nor 
suicidality emerged as a concern with deutetrabenazine 
or valbenazine, with placebo-level rates in the acute trials 
(deutetrabenazine: depression: 1%–4%; suicidality: 0%–3%; 
valbenazine: depression: 0%–1%; suicidality: 0%–4.2%) 
and illness base-rate frequencies82–85 in the long-term studies 
lasting up to 1 year (deutetrabenazine: depression: 6%–20%; 
suicidality: 0%–13%; valbenazine: depression: 2.6%–3.2%; 
suicidality: 4.5%–4.5%). These reassuring results are 
reflected by an absence of a black box labeling by the FDA 
for both deutetrabenazine and valbenazine in the patient 
population with TD with regard to depression and suicidal-
ity. However, results are currently based on selected patient 
populations agreeing to participate in research studies. Since 
the vast majority of patients with TD (apart from those with 
gastrointestinal conditions and metoclopramide therapy) have 
an underlying psychiatric condition, mainly schizophrenia or 
schizoaffective disorder and mood disorders (roughly two-
thirds and one-third in the valbenazine or deutetrabenazine 
trials, respectively), they have an illness-inherent risk for the 
emergence or worsening of depression and suicidality.82–85 
Therefore, despite the current absence of a signal for depres-
sion and suicidal behavior in the deutetrabenazine and 
valbenazine studies, clinicians need to monitor mood status 
and suicidality in patients on VMAT-2 inhibitors, be it ill-
ness related or as part of an adverse effect. Moreover, since 
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patients with active major depression or suicidality were 
excluded from the regulatory trials with VMAT-2 inhibitors, 
their safety in these populations is currently unclear. 
The results of this meta-analysis need to be interpreted 
within its strengths and limitations. This meta-analysis has 
the following strengths. First, to our knowledge, this is the 
first comprehensive meta-analysis assessing the efficacy 
and safety of deutetrabenazine and valbenazine in TD. 
Moreover, given the conservative choice not to consider 
post hoc analyses from individual publications (which yield 
significant results in single trials as opposed to some non-
significant findings from ITT or prespecified mITT data56,57), 
our significant results can be considered solid and unlikely 
be the result of a bias (Table 4). Moreover, results were 
confirmed in diagnostic subgroups. Finally, central ratings 
by blinded evaluators, which was applied in all DBRPCTs 
included in the meta-analysis and in both extension studies 
with deutetrabenazine and valbenazine, provides an unbiased 
and methodologically superior outcome assessment.86
However, some limitations should also be considered 
that are mainly due to the available evidence. Tetrabenazine 
essentially lacks sufficiently large and methodologically 
sound data from sufficiently large DBRPCTs to evaluate its 
utility in patients with TD. No RCT that compares different 
VMAT-2 inhibitors head-to-head currently exists. More-
over, all included trials evaluating the efficacy and safety 
of deutetrabenazine and valbenazine were industry-funded. 
However, results from this meta-analysis did not suggest the 
presence of any publication bias. Furthermore, results from 
patient-rated outcomes were inconsistent, and data on the 
functional impact of TD reduction with VMAT-2 inhibitors 
and information provided by family members/caregivers 
are lacking. Moreover, data regarding whether valbenazine 
or deutetrabenazine is effective in milder forms of TD are 
missing. Finally, patients included in the registration trials 
were psychiatrically stable and did not have active major 
depressive disorder or active suicidality (although patients 
with a history of suicidality were eligible for the studies). 
Thus, generalizability of the results to a more severely 
psychiatrically ill population with TD is currently not clear. 
Nevertheless, results from this meta-analysis confirm statisti-
cally and clinically relevant efficacy of deutetrabenazine and 
valbenazine in patients with TD, indicating their safety and 
tolerability in this important and previously underserved 
patient population.
Conclusion
Deutetrabenazine and valbenazine are FDA approved for 
TD and have at present the best high-quality evidence 
supporting their efficacy for TD, at the dose of 24–36 mg/day 
for deutetrabenazine and 40–80 mg/day for valbenazine, 
likely with a positive dose–response relationship. Moreover, 
the efficacy seems to progress further beyond the acute 
6–12 weeks, as treatment continues for up to 1 year, both 
in patients with schizophrenia or schizoaffective disorder 
and in patients with mood disorders. Both deutetrabenazine 
and valbenazine are safe, at least in the studied, psychiatri-
cally stable patient populations, and according to meta-
analytic results, neither of the 2 agents seems to have an 
increased risk for depression or suicidality in stable patients 
with TD.86 
Tetrabenazine has no high-quality evidence for its effi-
cacy or safety in patients with TD and should, at best, be 
considered a third-line, off-label treatment for TD, unless 
until methodologically sound trials, ideally comparing tet-
rabenazine with other VMAT-2 inhibitors, show its evental 
non-inferiority regarding effiacy and tolerability compared 
with deutetrabenazine and valbenazine.
Additional RCTs with VMAT-2 inhibitors in patients 
with TD are needed, ideally targeting long-term safety in 
patients who are representative of clinical samples as well as 
targeting functionality and quality of life, rated by clinicians, 
patients, and family members/caregivers. Furthermore, head-
to-head comparisons of the 2 FDA-approved agents should 
be conducted. In addition, studies should look to identify 
predictors of response and remission of TD as well as of 
subgroups in whom the VMAT-2 inhibitor may successfully 
be withdrawn after remission of TD.50 Finally, strategies for 
patients not responding sufficiently to the currently available 
VMAT-2 inhibitors also require further study.
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Table S1 Trials excluded with reasons
Trial identifier on ClinicalTrials.gov Drug Reason for exclusion
NCT02509793 Tetrabenazine No tardive dyskinesia
NCT01834911 Tetrabenazine No tardive dyskinesia
NCT01133353 Tetrabenazine No tardive dyskinesia
NCT00362804 Tetrabenazine No tardive dyskinesia
NCT00219804 Tetrabenazine No tardive dyskinesia
NCT00632645 Tetrabenazine No tardive dyskinesia
NCT01451463 Tetrabenazine No tardive dyskinesia
NCT01897896 Tetrabenazine No tardive dyskinesia
NCT02844179 Tetrabenazine No tardive dyskinesia
NCT01795859 Tetrabenazine No tardive dyskinesia
NCT02236754 Tetrabenazine No tardive dyskinesia
NCT02582736 Tetrabenazine No tardive dyskinesia
NCT02138864 Tetrabenazine No tardive dyskinesia
NCT02191358 Tetrabenazine No tardive dyskinesia
NCT01734733 Tetrabenazine No tardive dyskinesia
NCT00642057 Tetrabenazine No results available
NCT01543321 Tetrabenazine Currently recruiting patients/no results
NCT02736955 Tetrabenazine Currently recruiting patients/no results
NCT01795859 Deutetrabenazine No tardive dyskinesia
NCT02674321 Deutetrabenazine No tardive dyskinesia
NCT01897896 Deutetrabenazine No tardive dyskinesia
NCT02198794 Deutetrabenazine No results available
NCT01910480 valbenazine No tardive dyskinesia
NCT01916993 valbenazine No tardive dyskinesia
NCT02879578 valbenazine No tardive dyskinesia
NCT02581865 valbenazine No tardive dyskinesia
NCT02679079 valbenazine No tardive dyskinesia
NCT02256475 valbenazine No tardive dyskinesia
NCT01267188 valbenazine No results available
NCT02736955 valbenazine No results available
